THC therapy tanks in PhI, sending Zynerba's stock tumbling yet again
Zynerba’s stock $ZYNE is getting crushed yet again after news that its THC therapy has flopped in a Phase I trial. At least this time, they’re finding out early.
The Devon, Pennsylvania-based company was testing its transdermal patch meant to deliver THC, the psychoactive cannabinoid in cannabis, as a pro-drug in healthy volunteers. The hope was to make a THC therapy that didn’t have to be taken orally, which can cause high peak levels of THC in the blood causing increased psychoactive side effects. Unfortunately, the company wasn’t able to get ZYN001 to take. The Phase I study results indicated that target blood levels of 5 to 15 ng/ml THC were not achieved.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.